Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$2.33
-5.7%
$1.31
$0.60
$3.08
$190.27M1.17361,637 shs360,722 shs
Organogenesis stock logo
ORGO
Organogenesis
$3.27
+4.5%
$3.70
$2.28
$6.71
$414.81M1.631.15 million shs656,448 shs
Rain Enhancement Technologies Holdco, Inc. stock logo
RAIN
Rain Enhancement Technologies Holdco
$3.05
-6.2%
$1.21
$0.82
$11.32
$23.15M-0.2214,383 shs16,227 shs
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$4.63
-3.5%
$4.47
$3.55
$16.11
$209.66M0.52302,654 shs93,749 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
0.00%-9.69%+155.04%+173.92%+31.64%
Organogenesis stock logo
ORGO
Organogenesis
0.00%+3.15%+0.31%-32.99%+32.39%
Rain Enhancement Technologies Holdco, Inc. stock logo
RAIN
Rain Enhancement Technologies Holdco
-6.15%-17.70%-56.24%+45.24%+152.07%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
0.00%0.00%+9.46%-7.40%-61.13%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
2.9151 of 5 stars
3.74.00.00.01.81.70.6
Organogenesis stock logo
ORGO
Organogenesis
4.6245 of 5 stars
3.33.00.04.34.24.20.6
Rain Enhancement Technologies Holdco, Inc. stock logo
RAIN
Rain Enhancement Technologies Holdco
N/AN/AN/AN/AN/AN/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
3.2886 of 5 stars
4.42.00.00.02.12.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
3.33
Buy$5.50136.05% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.50
Moderate Buy$5.5068.20% Upside
Rain Enhancement Technologies Holdco, Inc. stock logo
RAIN
Rain Enhancement Technologies Holdco
0.00
N/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
2.82
Moderate Buy$15.60236.93% Upside

Current Analyst Ratings Breakdown

Latest YMAB, ORGO, IMAB, and RAIN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$20.00 ➝ $15.00
5/28/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$21.00 ➝ $18.00
5/19/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $11.00
5/14/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $14.00
5/14/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.00
4/22/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underperform$3.00
4/4/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
4/4/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
3/21/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$22.00 ➝ $12.00
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$3.89M48.91N/AN/A$2.47 per share0.94
Organogenesis stock logo
ORGO
Organogenesis
$482.04M0.86$0.21 per share15.67$2.09 per share1.56
Rain Enhancement Technologies Holdco, Inc. stock logo
RAIN
Rain Enhancement Technologies Holdco
N/AN/AN/AN/A($0.96) per shareN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$87.68M2.39N/AN/A$2.05 per share2.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.17N/AN/AN/A-3.46%-4.00%-2.26%8/6/2025 (Estimated)
Rain Enhancement Technologies Holdco, Inc. stock logo
RAIN
Rain Enhancement Technologies Holdco
-$4.53MN/A0.00N/AN/AN/A-43.86%N/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$29.67M-$0.64N/AN/AN/A-31.84%-30.59%-22.70%8/11/2025 (Estimated)

Latest YMAB, ORGO, IMAB, and RAIN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Rain Enhancement Technologies Holdco, Inc. stock logo
RAIN
Rain Enhancement Technologies Holdco
N/A-$0.20N/A-$0.20N/AN/A
5/13/2025Q1 2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$0.22-$0.12+$0.10-$0.12$19.97 million$20.90 million
5/8/2025Q1 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Rain Enhancement Technologies Holdco, Inc. stock logo
RAIN
Rain Enhancement Technologies Holdco
N/AN/AN/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/A
22.35
22.35
Organogenesis stock logo
ORGO
Organogenesis
N/A
4.12
3.67
Rain Enhancement Technologies Holdco, Inc. stock logo
RAIN
Rain Enhancement Technologies Holdco
N/A
0.09
0.09
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/A
4.77
4.35

Institutional Ownership

CompanyInstitutional Ownership
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38.38%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Rain Enhancement Technologies Holdco, Inc. stock logo
RAIN
Rain Enhancement Technologies Holdco
25.79%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
70.85%

Insider Ownership

CompanyInsider Ownership
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
22.10%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Rain Enhancement Technologies Holdco, Inc. stock logo
RAIN
Rain Enhancement Technologies Holdco
17.40%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
19.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38081.66 million63.61 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.85 million84.99 millionOptionable
Rain Enhancement Technologies Holdco, Inc. stock logo
RAIN
Rain Enhancement Technologies Holdco
637.59 million6.27 millionNo Data
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
15045.28 million36.36 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

I-Mab stock logo

I-Mab NASDAQ:IMAB

$2.33 -0.14 (-5.67%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$2.39 +0.06 (+2.58%)
As of 06/18/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$3.27 +0.14 (+4.47%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$3.27 0.00 (0.00%)
As of 06/18/2025 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Rain Enhancement Technologies Holdco stock logo

Rain Enhancement Technologies Holdco NASDAQ:RAIN

As of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.

Y-mAbs Therapeutics stock logo

Y-mAbs Therapeutics NASDAQ:YMAB

$4.63 -0.17 (-3.54%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$4.63 0.00 (0.00%)
As of 06/18/2025 05:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.